LDR Holding Corp

LDR — Technical Presentation (November 2014)

18 slides from LDR's technical presentation, Nov 14, 2014

  1. Slide 1: Mobi-C 5 Year 1 and 2 Level IDE Study Results

    Mobi-C® 5 Year 1 and 2 Level IDE Study Results

  2. Slide 2: Study Design

    2 • Prospective, randomized, multi-center concurrently controlled, FDA IDE clinical trial: – Investigational device: Mobi-C® Cervical Disc. – Control: ACDF. – Non-inferiority study with 2:1 randomization (TDR:ACDF). • One-level and two-level trial arms were conducted at 24 sites across the U.S. • Ou

  3. Slide 3: Patient Sample

    3 • One-level trial arm enrolled 245 patients randomized in a 2:1 ratio (TDR:ACDF): – 164 TDR patients and 81 ACDF patients. • Two-level trial arm enrolled 330 patients randomized in a 2:1 ratio (TDR:ACDF): – 225 TDR patients and 105 ACDF patients. • One investigational training case was included fo

  4. Slide 4: Overall Success

    4 • FDA predefined protocol – NDI Success • Improvement in NDI of at least 15/50 points in subjects with a baseline NDI score of ≥ 30/50 points, or a 50% improvement in subjects with a baseline NDI score of <30/50 points – No study failures due to secondary surgical interventions at the index level

  5. Slide 5: Results from one-level comparative study of Mobi-C to ACDF

    5 • 245 patients enrolled into a prospective, non-inferiority, unmasked, concurrently controlled, randomized 2:1 ratio (TDR:ACDF) study. – 164 TDR patients and 81 ACDF patients • All patients were treated for intractable radiculopathy with or without neck pain or myelopathy due to a single-level abn

  6. Slide 6: 1-Level Overall Study Success

    6 1-Level Overall Study Success *Non-inferiority of Mobi-C over ACDF (p<0.0001), Farrington-Manning test **Statistical superiority of Mobi-C over ACDF (p<0.0001), Fisher Exact test 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 12 Months 24 Months 36 Months 48 Months 60 Months Pa ti e nt P o pulatio n

  7. Slide 7: 1-Level Mean NDI Scores

    7 1-Level Mean NDI Scores *Statistically significant difference between treatment groups for change from baseline (p<0.05, t-test) 0 10 20 30 40 50 60 Baseline 6 Weeks 3 Months 6 Months 12 Months 18 Months 24 Months 36 Months 48 Months 60 Months NDI Sc o re Mobi-C (1- Level) ACDF (1- Level) * [ * [

  8. Slide 8: 1-Level NDI Success

    8 1-Level NDI Success 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 6 Weeks 3 Months 6 Months 12 Months 18 Months 24 Months 36 Months 48 Months 60 Months Pa ti e nt P o pulatio n Mobi-C (1- Level) ACDF (1- Level) * [ *Significant difference between groups (Fisher’s exact test, p < 0.05)

  9. Slide 9: 1-Level Reoperation Rates

    9 1-Level Reoperation Rates 0% 2% 4% 6% 8% 10% 12% 14% 16% 18% 20% 24 Months 36 Months 48 Months 60 Months Pa ti e nt P o pulatio n Mobi-C (1- Level) ACDF (1- Level) * [ * [ * [ * [ *Significant difference between groups (Fisher’s exact test, p < 0.05)

  10. Slide 10: 1-Level Range of Motion

    10 1-Level Range of Motion F/E = Flexion/Extension; LB = Left/Right Lateral Bending 0 2 4 6 8 10 12 Baseline 6 Weeks 3 Months 6 Months 12 Months 18 Months 24 Months 36 Months 48 Months 60 Months R an ge of Motion (deg rees ) Mobi-C (1- Level) F/E Mobi-C (1- Level) LB ACDF (1- Level) F/E ACDF (1- Lev

  11. Slide 11: 1-Level Adjacent Level Degeneration

    11 1-Level Adjacent Level Degeneration 0% 10% 20% 30% 40% 50% 60% 12 Months 24 Months 36 Months 48 Months 60 Months 12 Months 24 Months 36 Months 48 Months 60 Months Superior Adjacent Level Inferior Adjacent Level Pati e n t P opulatio n Mobi-C (1- Level) ACDF (1- Level) * [ * [ * [ * [ * [ * [ Usin

  12. Slide 12: Results from two-level comparative study of Mobi-C to ACDF

    12 • 330 patients enrolled into a prospective, non-inferiority, unmasked, concurrently controlled, randomized 2:1 ratio (TDR:ACDF) study. – 225 TDR patients and 105 ACDF patients • All patients were treated for intractable radiculopathy with or without neck pain or myelopathy due to a two contiguous

  13. Slide 13: 2-Level Overall Study Success

    13 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 12 Months 24 Months 36 Months 48 Months 60 Months P atie n t P op u la tio n Mobi-C (2- Level) ACDF (2- Level) 2-Level Overall Study Success * Non-inferiority of Mobi-C over ACDF (p<0.0001), Farrington-Manning test **Statistical superiority of Mobi-C ov

  14. Slide 14: 2-Level Mean NDI Scores

    14 2-Level Mean NDI Scores 0 10 20 30 40 50 60 Baseline 6 Weeks 3 Months 6 Months 12 Months 18 Months 24 Months 36 Months 48 Months 60 Months NDI Sc o re Mobi-C (2- Level) ACDF (2- Level) * [ * [ * [ * [ * [ * [ * [ * [ * [ *Statistically significant difference between treatment groups for change fr

  15. Slide 15: 2-Level NDI Success

    15 2-Level NDI Success 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 6 Weeks 3 Months 6 Months 12 Months 18 Months 24 Months 36 Months 48 Months 60 Months P atie n t P op u la tio n Mobi-C (2- Level) ACDF (2- Level) * [ * [ * [ * [ * [ * [ * [ * [ * [ *Significant difference between groups (Fisher’s e

  16. Slide 16: 2-Level Reoperation Rates

    16 2-Level Reoperation Rates *Significant difference between groups (Fisher’s exact test, p < 0.05) * [ 0% 2% 4% 6% 8% 10% 12% 14% 16% 18% 20% 24 Months 36 Months 48 Months 60 Months P atie n t P o p u la tio n Mobi-C (2- Level) ACDF (2- Level) * [ * [ * [ * [

  17. Slide 17: 2-Level Range of Motion

    17 2-Level Range of Motion F/E = Flexion/Extension; LB = Left/Right Lateral Bending 0 2 4 6 8 10 12 Baseline 3 Months 6 Months 12 Months 18 Months 24 Months 36 Months 48 Months 60 Months R an ge of Motion (deg rees ) Superior Index Level Mobi-C (2- Level) F/E Mobi-C (2- Level) LB ACDF (2- Level) F/E

  18. Slide 18: 2-Level Adjacent Level Degeneration

    18 0% 10% 20% 30% 40% 50% 60% 70% 80% 12 Months 24 Months 36 Months 48 Months 60 Months 12 Months 24 Months 36 Months 48 Months 60 Months Superior Adjacent Level Inferior Adjacent Level P atie n t P op u la tion Mobi-C (2- Level) ACDF (2- Level) 2-Level Adjacent Level Degeneration Using Kellgren-Law

LDR Holding — Technical Presentation (November 2014) on 6ix